SCHEMBL6380677

SCHEMBL6380677

COc1ccc(NS(=O)(=O)c2cccc(C(F)(F)F)c2)c(C(=O)O)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC20A2 Q08357 1/20 0.71
SLC20A1 Q8WUM9 1/20 0.71
MEN1 O00255 1/20 0.69
GAA P10253 1/20 0.69
KMT2A Q03164 1/20 0.69
ACLY P53396 1/20 0.60
AKR1C3 P42330 1/20 0.59
AKR1C2 P52895 1/20 0.59
USP2 O75604 1/20 0.58
USP8 P40818 1/20 0.58
KDM1A O60341 3/20 0.57
NR3C1 P04150 1/20 0.54
PGR P06401 1/20 0.54
AR P10275 1/20 0.54
ESR2 Q92731 1/20 0.54
PLAU P00749 1/20 0.52
PLAT P00750 1/20 0.52
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
IDH2 P48735 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12201483 0.90 SLC20A2 (0.72) SLC20A2SLC20A1MEN1GAAKMT2A
SCHEMBL7572438 0.86 SLC20A2 (0.63) SLC20A2SLC20A1MEN1GAAKMT2A
SCHEMBL23141255 0.85 KDM1A (0.74) SLC20A2SLC20A1MEN1GAAKMT2A
SCHEMBL7128814 0.83 SLC20A2 (1.00) SLC20A2SLC20A1MEN1GAAKMT2A
SCHEMBL3985583 0.82 METAP2 (0.72) SLC20A2SLC20A1MEN1GAAKMT2A
SCHEMBL7454156 0.80 MEN1 (0.72) SLC20A2SLC20A1MEN1KMT2A
SCHEMBL7567283 0.80 PLAU (0.62) SLC20A2SLC20A1MEN1GAAKMT2A
SCHEMBL23141186 0.80 KDM1A (0.81) MEN1GAAKMT2AACLYKDM1A
SCHEMBL7569668 0.79 KMT2A (0.76) SLC20A2SLC20A1MEN1GAAKMT2A
SCHEMBL23200342 0.77 MEN1 (0.66) MEN1GAAKMT2APGRKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7332608-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-19 US disclosed
US-7332608-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-19 US disclosed
US-7235690-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-26 US disclosed
US-7235690-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-26 US disclosed
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-24 US disclosed
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-24 US disclosed
WO-2005113490-A1 SULFONE-CONTAINING PRODRUGS ICAGEN, INC. (US) 2005-12-01 WO disclosed
US-20050267032-A1 Sulfone-containing prodrugs ICAGEN, INC. (US) 2005-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267032-A1 Sulfone-containing prodrugs KCNQ5, KCNE1, KCNH2 SLC20A2 48/4885SLC20A1 40/4885MEN1 2143/4885
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE KCNH1, KCNH2, KCNJ2 SLC20A2 3088/4885SLC20A1 2731/4885MEN1 3308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.